White adipose tissue dysfunction drives cardiometabolic alterations in obesity through impaired expansion, adipocyte hypertrophy, and inflammation, necessitating emerging tools to assess functionality.
White adipose tissue (AT) dysfunction plays an important role in the development of cardiometabolic alterations associated with obesity. AT dysfunction is characterized by the loss of the expansion capacity of the AT, an increment in adipocyte hypertrophy, and changes in the secretion profile of adipose cells, associated with accumulation of macrophages and inflammation. Since not all people with an excess of adiposity develop comorbidities, it is necessary to find simple tools that can evidence AT dysfunction and allow the detection of those people with the potential to develop metabolic alterations. This review focuses on the current pathophysiological mechanisms of white AT dysfunction and emerging measurements to assess its functionality.
Santillana et al. (2023) conducted a review in White adipose tissue dysfunction and obesity. White adipose tissue dysfunction drives cardiometabolic alterations in obesity through impaired expansion, adipocyte hypertrophy, and inflammation, necessitating emerging tools to assess functionality.